ECSP20060179A - Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro - Google Patents
Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puroInfo
- Publication number
- ECSP20060179A ECSP20060179A ECSENADI202060179A ECDI202060179A ECSP20060179A EC SP20060179 A ECSP20060179 A EC SP20060179A EC SENADI202060179 A ECSENADI202060179 A EC SENADI202060179A EC DI202060179 A ECDI202060179 A EC DI202060179A EC SP20060179 A ECSP20060179 A EC SP20060179A
- Authority
- EC
- Ecuador
- Prior art keywords
- bupropion
- dosage forms
- enantiomerically enriched
- methods
- pure bupropion
- Prior art date
Links
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 title abstract 3
- 229960001058 bupropion Drugs 0.000 title abstract 3
- 239000002552 dosage form Substances 0.000 title abstract 3
- SNPPWIUOZRMYNY-SECBINFHSA-N (R)-bupropion Chemical compound CC(C)(C)N[C@H](C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-SECBINFHSA-N 0.000 abstract 2
- SNPPWIUOZRMYNY-VIFPVBQESA-N (S)-bupropion Chemical compound CC(C)(C)N[C@@H](C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-VIFPVBQESA-N 0.000 abstract 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 229960001985 dextromethorphan Drugs 0.000 abstract 1
- 230000000155 isotopic effect Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente descripción se describen formas de dosificación de (S)-bupropión enriquecido enantioméricamente o (R)-bupropión enriquecido enantioméricamente. El (S)-bupropión o (R)-bupropión puede estar enriquecido con deuterio o pueden tener una abundancia isotópica natural. Estas formas de dosificación pueden administrarse, con la alimentación o en ayunas, para tratar una afección mencionada en la presente descripción, para lograr un cierto parámetro farmacocinético de un bupropión o un metabolito de un bupropión, y/o para mejorar los niveles plasmáticos de dextrometorfano.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634718P | 2018-02-23 | 2018-02-23 | |
| US201962794469P | 2019-01-18 | 2019-01-18 | |
| US201962809480P | 2019-02-22 | 2019-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP20060179A true ECSP20060179A (es) | 2020-12-31 |
Family
ID=67688503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202060179A ECSP20060179A (es) | 2018-02-23 | 2020-09-23 | Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP3755312A4 (es) |
| JP (3) | JP2021513998A (es) |
| KR (3) | KR20240091043A (es) |
| CN (1) | CN112087999A (es) |
| AU (3) | AU2019223187B2 (es) |
| BR (1) | BR112020017179A2 (es) |
| CA (1) | CA3092076A1 (es) |
| CL (1) | CL2020002166A1 (es) |
| CR (1) | CR20200415A (es) |
| EC (1) | ECSP20060179A (es) |
| IL (2) | IL313368A (es) |
| MA (1) | MA51914A (es) |
| MX (2) | MX2020008704A (es) |
| NI (1) | NI202000056A (es) |
| NZ (1) | NZ767378A (es) |
| PE (1) | PE20211752A1 (es) |
| SG (1) | SG11202008056SA (es) |
| WO (1) | WO2019165379A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| BR112022005045A2 (pt) * | 2019-09-20 | 2022-07-05 | Axsome Therapeutics Inc | Forma de dosagem, uso e kit de (s)-bupropiona que é pelo menos 95% enantiomericamente pura |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2318960A1 (en) * | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (+)-bupropion |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| EP1575565B1 (en) * | 2003-08-08 | 2010-01-06 | Biovail Laboratories International Srl | Modified-release tablet of bupropion hydrochloride |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9198905B2 (en) * | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9732031B2 (en) * | 2013-12-20 | 2017-08-15 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
-
2019
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/ja active Pending
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/zh active Pending
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/en unknown
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
- 2019-02-25 MA MA051914A patent/MA51914A/fr unknown
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/pt unknown
- 2019-02-25 KR KR1020247017593A patent/KR20240091043A/ko active Application Filing
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/es unknown
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/ko active Application Filing
- 2019-02-25 CR CR20200415A patent/CR20200415A/es unknown
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/es unknown
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/en active Pending
- 2019-02-25 IL IL313368A patent/IL313368A/en unknown
- 2019-02-25 IL IL276871A patent/IL276871B1/en unknown
- 2019-02-25 CA CA3092076A patent/CA3092076A1/en active Pending
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/ko not_active IP Right Cessation
-
2020
- 2020-08-20 MX MX2023009281A patent/MX2023009281A/es unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/es unknown
- 2020-08-21 NI NI202000056A patent/NI202000056A/es unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/es unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521B2/en active Active
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/ja active Pending
-
2024
- 2024-03-15 JP JP2024041381A patent/JP2024075655A/ja active Pending
- 2024-08-17 AU AU2024205858A patent/AU2024205858A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NI202000056A (es) | 2021-01-11 |
| BR112020017179A2 (pt) | 2020-12-22 |
| IL313368A (en) | 2024-08-01 |
| IL276871B1 (en) | 2024-07-01 |
| EP3755312A1 (en) | 2020-12-30 |
| WO2019165379A1 (en) | 2019-08-29 |
| KR20210003091A (ko) | 2021-01-11 |
| AU2024205858A1 (en) | 2024-09-05 |
| CL2020002166A1 (es) | 2020-10-23 |
| MX2023009281A (es) | 2023-08-17 |
| MA51914A (fr) | 2020-12-30 |
| KR20230075531A (ko) | 2023-05-31 |
| CN112087999A (zh) | 2020-12-15 |
| NZ767378A (en) | 2024-03-22 |
| IL276871A (en) | 2020-10-29 |
| SG11202008056SA (en) | 2020-09-29 |
| AU2019223187A1 (en) | 2020-09-17 |
| KR20240091043A (ko) | 2024-06-21 |
| JP2021513998A (ja) | 2021-06-03 |
| CA3092076A1 (en) | 2019-08-29 |
| AU2019223187B2 (en) | 2022-07-28 |
| EP3755312A4 (en) | 2022-03-16 |
| JP2024075655A (ja) | 2024-06-04 |
| MX2020008704A (es) | 2020-12-07 |
| AU2022204521B2 (en) | 2024-09-05 |
| PE20211752A1 (es) | 2021-09-06 |
| JP2022153638A (ja) | 2022-10-12 |
| CR20200415A (es) | 2021-02-03 |
| AU2022204521A1 (en) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20060179A (es) | Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro | |
| UY36703A (es) | Composiciones y métodos para la administración de un polinucleótido en una planta | |
| UY32388A (es) | Composicion farmaceutica sólida que comprende amlodipina y losartan con estabilidad mejorada | |
| CL2016002560A1 (es) | Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación. | |
| WO2020061486A3 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| UY35988A (es) | Proceso para la producción de una solución inyectable de noradrenalina de baja concentración | |
| USD787607S1 (en) | Word game components set | |
| AR055682A1 (es) | Forma de dosificacion osmotica con aspectos de liberacion controlada y de liberacion rapida | |
| MX2018012800A (es) | Administracion de metabolitos de berberina. | |
| ECSP18015616A (es) | Tableta | |
| CL2022001178A1 (es) | Ligandos de la pseudoquinasa tyk2 | |
| CL2021001636A1 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
| BR112018074434A2 (pt) | composições farmacêuticas compreendendo safinamida | |
| MX2021001845A (es) | Un medicamento combinado que comprende fenilefrina y paracetamol. | |
| CO2018013792A2 (es) | Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo | |
| ECSP22030119A (es) | Formas de dosificación y métodos para bupropión enantioméricamente enriquecido o puro | |
| Nabila | In Vivo Antithrombotic Activity Test of Ginger (Zingiber officinale Rosc.) and Sappan Wood (Caesalpinia sappan L.) Extract Combination | |
| UA120529U (uk) | Спосіб збереження функції нирок у хворих, що страждають на подагру і метаболічний синдром | |
| DOP2019000233A (es) | Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tableta | |
| 刘欣 et al. | How to Face the Difficulty in Our Life | |
| IN2014MU00190A (es) | ||
| IT201700002235A1 (it) | Composizione per somministrazione orale utile nel trattamento del diabete e delle sindrome metaboliche in genere | |
| UA93429U (uk) | Спосіб підвищення ефективності профілактики судинних ускладнень у хворих на остеоартроз | |
| GT201500333A (es) | Composición farmacéutica sinergística de dos analgésicos con distinto perfil famacocinético |